Allogene Therapeutics Inc... (ALLO)
NASDAQ: ALLO
· Real-Time Price · USD
1.11
0.04 (3.74%)
At close: Aug 15, 2025, 2:35 PM
3.74% (1D)
| Bid | 1.11 |
| Market Cap | 243.89M |
| Revenue (ttm) | -22K |
| Net Income (ttm) | -252.32M |
| EPS (ttm) | -1.1 |
| PE Ratio (ttm) | -1.01 |
| Forward PE | -1.06 |
| Analyst | Buy |
| Ask | 1.12 |
| Volume | 4,780,054 |
| Avg. Volume (20D) | 3,769,227 |
| Open | 1.07 |
| Previous Close | 1.07 |
| Day's Range | 1.07 - 1.21 |
| 52-Week Range | 0.86 - 3.78 |
| Beta | 0.36 |
About ALLO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ALLO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ALLO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
+8.55%
Allogene Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
3 months ago
-15.68%
Allogene Therapeutics shares are trading lower after the company reported Q1 financial results. Also, Baird and Oppenheimer lowered their respective price targets on the stock.
2 months ago · https://www.defenseworld.net
Squarepoint Ops LLC Sells 168,152 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)Squarepoint Ops LLC cut its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 89.2% during the fourth quarter, according to the company in its most recent disclosu...
2 months ago · seekingalpha.com
Allogene Therapeutics: Buying Around A Potential ASCO Lazarus MomentAllogene's off-the-shelf CAR-T therapies offer scalable, rapid solutions with a diversified pipeline targeting hematologic malignancies, solid tumors, and autoimmune diseases. Upcoming ASCO data, espe...
